Pharma and agritech groups among those expected to make payments for information drawn from the living world
Pharmaceutical and a host of other companies will be expected to voluntarily pay into a new fund covering their use of genetic data, the UN COP16 biodiversity summit agreed, but countries failed to reach a wider agreement on global finance for nature after talks ran overtime and were suspended.
1 per cent of revenue would have meant a $67mn payment last year from Switzerland’s Roche, the biggest non-US pharma company by sales, alone. Expert observers to the negotiations noted that the use of the word “should”, rather than “shall”, meant that these would essentially be voluntary contributions by companies, rather than the mandatory levy that some countries had been pushing for.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pharma 4.0: Shaping the Future of Pharmaceutical ManufacturingThe evolution of Pharma 4.0 integrates advanced technologies, transforming drug development and manufacturing with improved efficiency and product quality.
Read more »
New combination treatment authorized for unresectable urothelial cancer patientsAstellas Pharma Ltd.
Read more »
How to streamline supply chain logistics for optimal pharma deliveryLearn how to streamline supply chain logistics in the pharmaceutical industry for optimal delivery. Discover strategies here.
Read more »
Evosep expanding capabilities with new headquarters to support rising needs in pharma and biotech for proteomicsEvosep, a global leader in proteomics solutions, is proud to announce its relocation to new headquarters in Odense.
Read more »
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the BoardCalluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.
Read more »
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indicationsCalluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.
Read more »